Is Ardelyx, Inc. (ARDX) a Buy, Sell, or Hold?
Ardelyx, Inc.
NASDAQ:ARDX
$5.16 USD
$0.02 (0.39%)
- Volume
- 2.65M
- Average Volume
- 4.04M
- Market Capitalization
- $1.27B
- P/E Ratio
- -21.94
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $8.40
- Year Low
- $4.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.49
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael G. Raab |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ARDX |
| CUSIP | 039697107 |
| CIK | 0001437402 |
| Web | https://www.ardelyx.com |
| Phone | 510 745 1700 |
| Currency | USD |
| Employees | 489 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.40 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.49 |
| Quick Ratio | 3.28 |
| Cash Ratio | 0.28 |
Sales & Book Value
| Annual Sales | $407.32M |
| Price / Sales | 2.98 |
| Cash Flow | -0.15 |
| Price / Cash Flow | -33.99 |
| Price / Book | 8.54 |
Price Target and Rating
| Average Stock Price Forecast | $17.00 |
| High Stock Price Forecast | $18.00 |
| Low Stock Price Forecast | $15.00 |
| Forecast Upside/Downside | -69.65% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.26 |
| Trailing P/E Ratio | -21.94 |
| PEG Ratio | 2.07 |
| P/E Growth | 2.07 |
| Net Income | $-61.6M |
| Net Margin | -13.58% |
| Pretax Margin | -13.55% |
| Return on Equity | -38.11% |
| Return on Assets | -11.51% |
Financials Score
| AltmanZ Score | 0.72 |
| Piotroski Score | 2.00 |
| Working Capital | 272.3M |
| Total Assets | 504.51M |
| Ebit | -28.89M |
| Market Cap | 1.27B |
| Total Liabilities | 355.88M |
Poll Results
About Ardelyx, Inc. (NASDAQ:ARDX) Stock
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (eleva ... ted serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
2026-06-23 18:43:39
According to an SEC filing, an executive at Ardelyx reported selling 81,898 directly held Common Stock shares on June 18, 2026, generating a transaction value of $490,000. The sale represented 17.8% of Williams's direct Common Stock holdings, reducing her Common Stock position to 378,195 shares (direct) post-transaction.
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
2026-06-04 08:07:54
Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability.
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
2026-05-19 08:01:00
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.
Ardelyx: Low Price, But High Implied Valuation
2026-05-08 10:55:58
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside.
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings
2026-05-07 08:01:00
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biomarkers at the National Kidney Foundation's (NKF) Spring Clinical Meetings, currently underway in New Orleans.
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
2026-04-30 22:01:35
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
2026-04-30 19:26:44
Ardelyx (ARDX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
2026-04-30 19:01:18
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Frequently Asked Questions
-
What is the current Ardelyx, Inc. (ARDX) stock price?
-
Ardelyx, Inc.(NASDAQ:ARDX) stock price is $5.16 in the last trading session. During the trading session, ARDX stock reached the peak price of $8.4 while $4.075 was the lowest point it dropped to. The percentage change in ARDX stock occurred in the recent session was 0.39% while the dollar amount for the price change in ARDX stock was $0.02.
-
ARDX's industry and sector of operation?
-
The NASDAQ listed ARDX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARDX?
-
Sue Hohenleitner | Chief Financial Officer
Laura A. Williams | Chief Patient Officer & Interim Chief Medical Officer
Eric Duane Foster | Chief Commercial Officer
Caitlin Lowie | Vice President of Corporate Communications & Investor Relations
Felecia W. Ettenberg | Chief Legal Officer -
How many employees does ARDX have?
-
Number of ARDX employees currently stands at 489. ARDX operates from 400 Fifth Avenue, Waltham, MA 02451, US.
-
Link for ARDX official website?
-
Official Website of ARDX is: https://www.ardelyx.com
-
How do I contact ARDX?
-
ARDX could be contacted at phone #510 745 1700 and can also be accessed through its website. ARDX operates from 400 Fifth Avenue, Waltham, MA 02451, US.
-
How many shares of ARDX are traded daily?
-
The average number of ARDX shares traded daily for last 3 months was 4.04M.
-
What is the market cap of ARDX currently?
-
The market value of ARDX currently stands at $1.27B with its latest stock price at $5.16